• Cellbox Solutions

  Participated · Series A · Mar 2023

  Founded in 2017 and headquartered in Cologne, Germany, Cellbox Solutions offers patented warm-chain technology that keeps cell samples at stable physiological conditions for up to 48 hours during transit. Its flagship Cellbox™ devices function as portable CO₂ incubators, allowing pharmaceutical and biotechnology companies, research institutions, and universities to ship living cells, organoids, and tissues without freezing. More than 300 units are already deployed worldwide, underscoring early commercial traction. The systems are certified and compliant with International Air Transport Association regulations, broadening their applicability to global air transport. Newly raised funds will be used to scale international production and sales operations and to expand use cases across cell and gene therapies, IVF, and other life-science workflows. The company has also strengthened its leadership by appointing Dr. Bernd Muehlenweg as Chief Business Officer and Chief Financial Officer to guide the next growth phase.

• InfanDx

  Led · Series A · Mar 2022

  InfanDx focuses on developing and commercializing novel diagnostic solutions for acute and critical care conditions in newborns, with its lead product the HypoxE® Test for HIE. The HypoxE® Test is designed to reliably identify HIE within the first hours after birth to enable timely neuroprotective hypothermia treatment. The company is advancing the product through two prospective longitudinal cohort studies (AAMBI completed; BANON to be completed by end of Q1‑2022) to validate biomarkers and diagnostic tests. R&D activities are reported to be on track, and the company is developing prototype tests for laboratory and point‑of‑care settings plus a cloud‑based interpretation software for clinical decision support. InfanDx has headquarters in Cologne, Germany, a branch office in Berlin, and a wholly owned subsidiary in Boston, MA, USA. Recent financing activity has provided additional runway to reach key milestones and support planned US clinical development. InfanDx AG is a privately held neonatal diagnostics company focused on developing and commercializing rapid tests for acute and critical care conditions in newborns. Its lead product, the HypoxE® test, is designed to identify hypoxic‑ischemic encephalopathy (HIE) within the first hours after birth to support timely neuroprotective hypothermia treatment. The HypoxE® program is in advanced clinical development and leverages two prospective longitudinal cohorts—AAMBI (completed) and BANON (nearing completion)—to validate biomarkers and the diagnostic algorithm. Proceeds from the recent Series A will fund final design and validation of the biomarker panel and interpretative algorithm, development of prototype tests for laboratory and point‑of‑care settings, and a cloud‑based interpretation software for clinical decision support. The company closed a first Series A totaling EUR 4 million to reach key value‑creating milestones over the next 12–18 months and is targeting a Series B in the second half of 2022 to support European launches and potential U.S. FDA approval. InfanDx was incorporated in 2010, incubated at the Life Science Incubator in Bonn, and in 2018 relocated to BioCampus Cologne.

No current team members are available.